Related references
Note: Only part of the references are listed.The value of drug repositioning in the current pharmaceutical market
E.L. Tobinick
DRUG NEWS & PERSPECTIVES (2009)
Disability and survival in Duchenne muscular dystrophy
M. Kohler et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2009)
Functional Substitution by TAT-Utrophin in Dystrophin-Deficient Mice
Kevin J. Sonnemann et al.
PLOS MEDICINE (2009)
A specific mechanism for nonspecific activation in reporter-gene assays
Douglas S. Auld et al.
ACS CHEMICAL BIOLOGY (2008)
Establishment of a Cell-Based Assay to Screen Regulators of the Hypoxia-Inducible Factor-1-Dependent Vascular Endothelial Growth Factor Promoter
Deng Bo Ji et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
Targeting Artificial Transcription Factors to the Utrophin A Promoter EFFECTS ON DYSTROPHIC PATHOLOGY AND MUSCLE FUNCTION
Yifan Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206
Miriam I. Rosenberg et al.
JOURNAL OF CELL BIOLOGY (2006)
Systemic administration of L-arginine benefits mdx skeletal muscle function
ER Barton et al.
MUSCLE & NERVE (2005)
L-arginine improves dystrophic phenotype in mdx mice
V Voisin et al.
NEUROBIOLOGY OF DISEASE (2005)
Identification of human dopamine D1-like receptor agonist using a cell-based functional assay
N Jiang et al.
ACTA PHARMACOLOGICA SINICA (2005)
Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy
YW Chen et al.
NEUROLOGY (2005)
The utrophin A 5′-untranslated region confers internal ribosome entry site-mediated translational control during regeneration of skeletal muscle fibers
P Miura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
JD Rothstein et al.
NATURE (2005)
Heregulin ameliorates the dystrophic phenotype in mdx mice
TOB Krag et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Nabumetone - Therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis
T Hedner et al.
DRUGS (2004)
Okadaic acid augments utrophin in myogenic cells
M Rodova et al.
NEUROSCIENCE LETTERS (2004)
Trends in development and approval times for new therapeutics in the United States
JM Reichert
NATURE REVIEWS DRUG DISCOVERY (2003)
Profiling drug-like properties in discovery research
L Di et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2003)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle
AP Weir et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models
M Durbeej et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2002)
Distinct regions in the 3′ untranslated region are responsible for targeting and stabilizing utrophin transcripts in skeletal muscle cells
AO Gramolini et al.
JOURNAL OF CELL BIOLOGY (2001)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
C Bombardier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Drug-like properties and the causes of poor solubility and poor permeability
CA Lipinski
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2000)